All In MedTech

Device Trial Radar · NCT02511678

Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases

Last checked: Nov 19, 2026Latest source record: Jul 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Feb 15, 2016

Primary completion

Mar 12, 2018

Study completion Mar 12, 2018

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Jul 30, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of cryoablation for palliation of painful metastases in participants with metastatic lesions involving bone who have failed, are not candidates for, or are not experiencing adequate pain relief from current pain therapies (for example, radiation, analgesics).

Conditions

  • Pain
  • Neoplasm Metastasis
  • Bone Metastasis of Diverse Origins

Interventions

  • CryoablationDevice

    The application of repeated freeze and thaw cycles to the identified tissues.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Worst Pain Scores as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) at Week 8Time frame: Baseline, Week 8

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • UCLA Ronald Reagan Medical Center

    Los Angeles, California

  • Emory University Hospital

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.